What is the importance of checking the nasal bone during the first‑trimester ultrasound at 13–14 weeks gestation?

Nasal Bone Assessment at 13-14 Weeks: A Powerful Adjunct to First-Trimester Aneuploidy Screening

Checking the nasal bone at 13-14 weeks gestation significantly improves the detection of fetal aneuploidy, particularly Down syndrome (trisomy 21), by enhancing first-trimester screening algorithms when combined with nuchal translucency and maternal serum markers. 1

Why Nasal Bone Assessment Matters

The absence of the nasal bone at 11-14 weeks is a powerful ultrasound marker of fetal aneuploidy that improves screening performance beyond nuchal translucency (NT) alone 1. Here's the clinical reasoning:

Enhanced Detection Rates

• Standard first-trimester combined screening (NT + maternal serum PAPP-A + free β-hCG) detects approximately 90% of affected pregnancies with a 5% false-positive rate 1
• Adding nasal bone assessment can push detection rates to 95% while reducing false-positives to 2.9%, or achieve 91% detection at just 1% false-positive rate 2
• NT measurement alone only detects 70% of trisomy 21 cases, making it insufficient as a standalone marker 1

The Biology Behind It

In fetuses with trisomy 21:

• 64-71% have absent or hypoplastic nasal bones at 11-14 weeks 3, 4
• Only 0.7-1.4% of chromosomally normal fetuses show absent nasal bones 4, 5
• This creates a positive likelihood ratio of 101 for trisomy 21 detection 4

Clinical Application Algorithm

When to assess:

• During routine first-trimester screening at 11-14 weeks (your 13-14 week timeframe is optimal)
• Feasible in 92-99% of patients using either transabdominal or transvaginal ultrasound 1, 4

How it changes management:

1. If nasal bone is absent + NT ≥3mm:

   • Immediate genetic counseling and offer invasive diagnostic testing (CVS or amniocentesis) 1
   • Approximately one-third of fetuses will have chromosomal abnormalities 1
   • Cell-free DNA testing is an alternative, but misses conditions like Noonan syndrome and 22q11.2 deletion 1

2. If nasal bone is absent but NT is normal:

   • Adjust aneuploidy risk calculations accordingly 1
   • Consider repeat evaluation, as 71% may show present nasal bone on re-examination, normalizing risk in 92% of initially screen-positive cases 6

3. If both nasal bone and NT are normal:

   • Reassuring, but continue with standard second-trimester anatomic survey 1

Important Caveats and Pitfalls

Technical challenges:

• Requires proper training and quality assurance programs (Fetal Medicine Foundation or Nuchal Translucency Quality Review standards) 1
• Significant inter-observer variability exists—ongoing quality assessment is critical 1
• Must use standardized views (mid-sagittal plane or retronasal triangle view) 4

Ethnic considerations:

• Black patients are more likely to have initially absent/uncertain nasal bone that becomes present on repeat examination 6
• Consider repeat evaluation before escalating to invasive testing in this population

Limitations:

• Some research suggests nasal bone has lower sensitivity (27%) and should not be used in risk calculation algorithms 7, though this contradicts the guideline consensus
• The marker is most useful when combined with other screening parameters, not in isolation 1

What nasal bone assessment does NOT replace:

• Second-trimester anatomic survey (only 50% of major anomalies detected at 11-14 weeks vs. 75% at 18-22 weeks) 1
• Fetal echocardiography in high-risk cases (NT alone is poor screening for congenital heart disease, detecting <25% of major defects) 1

The Bottom Line

Nasal bone assessment at 13-14 weeks is a high-specificity, moderate-to-high sensitivity marker that meaningfully improves aneuploidy detection when integrated into first-trimester screening protocols. It provides earlier reassurance or timely detection of abnormalities, enabling earlier and safer pregnancy termination options when chosen 1. The key is proper technique, appropriate training, and understanding that it functions best as part of a comprehensive screening algorithm—not as a standalone test.